

Review Article

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

Jesrine Hong^{1,2,3} and  Sailesh Kumar^{1,3}

¹Mater Research Institute, University of Queensland, Level 3, Aubigny Place, Raymond Terrace, South Brisbane, Queensland 4101, Australia; ²Department of Obstetrics and Gynecology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia; ³School of Medicine, The University of Queensland, Herston, Queensland 4006, Australia

Correspondence: Sailesh Kumar (sailesh.kumar@mater.uq.edu.au)



Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal morbidity and mortality worldwide. Normal placental development involves a series of highly regulated processes involving a multitude of hormones, transcription factors, and cell lineages. Failure to achieve this leads to placental dysfunction and related placental diseases such as pre-eclampsia and FGR. Early recognition of at-risk pregnancies is important because careful maternal and fetal surveillance can potentially prevent adverse maternal and perinatal outcomes by judicious pregnancy surveillance and careful timing of birth. Given the association between a variety of circulating maternal biomarkers, adverse pregnancy, and perinatal outcomes, screening tests based on these biomarkers, incorporating maternal characteristics, fetal biophysical or circulatory variables have been developed. However, their clinical utility has yet to be proven. Of the current biomarkers, placental growth factor and soluble fms-like tyrosine kinase 1 appear to have the most promise for placental dysfunction and predictive utility for FGR.

Introduction

A small for gestational age (SGA) infant is variably defined as one with an estimated fetal weight (EFW) or birthweight (BW) less than the 10th centile for gestation [1–3]. Globally, almost 21 million infants are born SGA each year, the majority in low-income and middle-income countries [4]. These infants are at higher risk of morbidity and mortality particularly if they are born preterm [5] and are also more likely to develop chronic health complications through childhood and in adulthood [6].

Although SGA and fetal growth restriction (FGR) are often used interchangeably, FGR is defined as an infant that has not achieved its genetic growth potential [7]; however, as this is inherently unknown, it is impossible to determine if any infant has indeed achieved that potential prenatally. Importantly, not all infants with FGR will be SGA and not all SGA infants will have FGR. Regardless of this caveat, many SGA/FGR liveborn infants will have low birth weight (LBW) defined as a BW <2500 g irrespective of gestational age. Worldwide, LBW is an important public health indicator, especially in settings where accurate gestational age assessment is not possible and prenatal assessment of fetal size or growth is not available [5,8].

Normal placental development [9] involves a combination of highly regulated processes requiring a plethora of angiogenic growth factors, hormones, transcription factors, cytokines and cell adhesion molecules [10]. Failure to establish a high capacitance, low pressure maternal fetal vascular interface [9] leads to placental dysfunction and is causally related to several obstetric syndromes including pre-eclampsia and FGR [11]. Although there is considerable overlap between the pathogenesis of

Received: 01 November 2022
Revised: 31 March 2023
Accepted: 04 April 2023

Version of Record published:
19 April 2023




Figure 1. Circulating maternal biomarkers derived from the placenta that are associated in placental dysfunction

A summary of various hormonal factors, polypeptides, glycoproteins, angiogenic factors, and nucleic acids, which are associated in placental dysfunction and pathophysiology of FGR.

pre-eclampsia and FGR, the relationship between the extent of failure of spiral artery conversion, gestation at onset, type of disease, maternal and infant phenotype as well as clinical outcomes remains poorly understood [12–14].

The challenge obstetricians face is identifying the truly growth restricted fetus regardless of size, as these are the infants that are most at risk of adverse outcomes. Because placental dysfunction leading to inadequate nutrient and oxygen transfer [15] accounts for the majority of SGA/FGR infants [16,17], many investigators have focused attention on circulating biomarkers indicative of aberrant placental function [18–20]. As there is currently no treatment for placental dysfunction, early recognition of at-risk pregnancies is important because careful maternal and fetal surveillance can be instituted and adverse outcomes potentially prevented by judicious timing of birth [21–23]. The aim of this narrative review is to provide an overview of available evidence regarding circulating biomarkers associated with placental dysfunction and to discuss their clinical utility for the prediction of FGR. A comprehensive review of PubMed, Cochrane Library, and CINAHL was performed to identify appropriate publications between 1995 and October 2022 relevant to this review.

Circulating biomarkers are broadly classified into: (1) hormonal factors, polypeptides, and glycoproteins; (2) angiogenic factors; and (3) cell-free nucleic acids [12,24] (Figure 1). Some of these biomarkers are potentially expressed as a consequence of epigenetic changes during placental development [25–28].

Hormonal factors, polypeptides, and glycoproteins

Table 1 lists various placental hormones, polypeptides, and glycoproteins associated with placental dysfunction and their potential roles for screening and diagnosis of FGR. These include beta-human chorionic gonadotrophin (β -hCG), pregnancy-associated plasma protein-A (PAPP-A), A Disintegrin and Metalloprotease 12 (ADAM12), placental protein 13 (PP13), alpha-fetoprotein (AFP), inhibin A, activin A, follistatin, placental growth hormone (PGH), neural cell adhesion molecule (N-CAM), fibroblast growth factor (FGF), Insulin-like growth factor-I (IGF-I), Insulin-like growth factor binding proteins-1, -3, -4 (IGFBP-1, IGFBP-3, and IGFBP-4), and serine protease inhibitor Kunitz type 1 (SPINT1).

β hCG, PAPP-A, and ADAM12

Lower concentrations of circulating maternal β hCG, PAPP-A, and ADAM12 measured at 11–14 weeks of gestation have been reported in women with SGA/FGR infants [29–33]. Pihl et al. observed that first trimester maternal serum concentrations of β hCG, PAPP-A, and ADAM12 in women with SGA infants (defined as BW <5th centile) were significantly lower compared with matched controls (β hCG: 0.74 vs. 1.04 multiples of median (MoM), PAPP-A: 0.64

Table 1 Circulating maternal biomarkers associated with FGR

Biomarkers	Functions	Maternal levels in FGR pregnancies	Key references
Hormonal factors, polypeptides, and glycoproteins			
Activin A	Regulation of endometrial receptivity, implantation of embryo, and trophoblast development	Unchanged	[51]
		Raised	[50]
ADAM12 ^a	Promotion of cell migration and trophoblast invasion	Reduced	[29,31,32,35,37]
AFP ^b	Function in human placenta is unclear	Raised in first and second trimester	[34,46,47]
		Reduced in third trimester	[48]
β-HCG ^c	Promotion of progesterone production by corpus luteal cells and maintenance of endometrial lining. Promotion of angiogenesis, immunosuppression, and growth of fetus organs	Reduced in first trimester	[30,32,37]
		Unchanged in second trimester	[34]
Follistatin	Inhibits the biological activity of Activin A. Inhibits follicular development in ovary by antagonizing follicle-stimulating hormone	Reduced	[50,51]
Inhibin A	Regulation of implantation and differentiation of developing embryo	Unchanged	[51–53]
		Raised	[50]
IGF-I ^d	Promotion of transplacental nutrient transfer to the fetus	Reduced	[58,61]
IGFBP-1 ^e	Regulation of implantation and endometrial growth	Reduced	[58,59]
IGFBP-3 ^e	Modulation of IGF-I effect in transplacental nutrient transfer	Unchanged	[58]
IGFBP-4 ^e	Regulation of IGF bioavailability	Raised	[60]
N-CAM ^f	Cell signaling, adhesion, proliferation, and differentiation in fetal development. Maintenance of tissue integrity and regeneration of neural and non-neural tissues during early development of fetus	Increased	[61]
PGH ^g	Regulation of placental and fetal growth. Stimulation of IGF-I secretion	Unchanged	[57]
PP13 ^h	Regulation of implantation and placental vascular development	Unchanged	[33,37,40–42,150]
		Reduced	[43]
PAPP-A ⁱ	Interaction with IGF and regulation of trophoblast and fetal growth	Reduced	[19,29,30,32,34,37]
SPINT1 ^j	Mediates secretion of trophoblast degradative enzymes that regulate invasion and remodeling of endometrial spiral arteries	Reduced	[68–70]
Angiogenic factors			
PlGF ^k	Angiogenic factor expressed in villous syncytiotrophoblast to promote development and maturation of placental vascular system	Reduced	[37,48,76,79,80,86,91,92,94–98,107,151–157]
		Increased	[158,159]
		Unchanged	[160,161]
sFlt-1 ^l	Antiangiogenic protein that antagonizes the actions of vascular endothelial growth factor and placental growth factor	Increased	[48,80,86,91,92,94–98,152–154,156–158,162–166]
		Reduced	[151,166,159]
		Unchanged	[107,155,160,167]
VEGF-A ^m	Promotes placental vasculogenesis and angiogenesis throughout pregnancy by promoting formation of angioblasts and mesenchymal villi	Increased	[158]
sEng ⁿ	Inhibits transforming growth factor beta (TGF-β)-mediated cell signaling and endothelial function	Increased	[111,112,166,168]
		Unchanged	[113,158]
FGF ^o	Regulates placental growth, differentiation, and angiogenesis	Increased	[61]
		Reduced	[63]

^aA Disintegrin and Metalloprotease 12.

^bAlpha-fetoprotein.

^cBeta-human chorionic gonadotrophin.

^dInsulin-like growth factor-I.

^eInsulin-like growth factor binding proteins-1, -3, and -4.

^fNeural cell adhesion molecule.

^gPlacental growth hormone.

^hPlacental protein 13.

ⁱPregnancy-associated plasma protein-A.

^jSerine protease inhibitor Kunitz type 1.

^kPlacental growth factor.

^lSoluble fms-like tyrosine kinase 1.

^mVascular endothelial growth factor-A.

ⁿSoluble endoglin.

^oFibroblast growth factor.

vs. 1.02 MoM and ADAM12: 0.74 vs. 0.97 MoM). Combining β hCG and PAPP-A yielded a detection rate of 26% with a false-positive rate (FPR) of 5% for an SGA infant. However, the addition of ADAM12 only very modestly improved the detection rate by a further 2% [32]. In another study, Poon et al. found that first trimester β hCG and PAPP-A concentrations in combination with maternal characteristics and fetal nuchal translucency measurement predicted birth of an SGA infant [30]. Maternal β hCG and PAPP-A MoM were significantly lower in SGA pregnancies, and combining maternal factors, nuchal translucency thickness, PAPP-A, and free β hCG concentrations resulted in the highest area under receiver-operating curve (AUROC) of 0.747 (95% CI: 0.735–0.760) and a detection rate of 37% for a FPR of 10% [30]. In contrast, however, a screening test later in pregnancy using a similar combination of biomarkers, maternal factors, and fetal biometry at 19–24 weeks of gestation performed poorly for the prediction of an SGA infant [34].

Other studies have shown that although there is good correlation between first trimester maternal serum ADAM12 concentrations with BW centile, it performs poorly as a standalone screening test [29]. A more recent study evaluated maternal plasma ADAM12 late in the third trimester (36 weeks) and despite finding significantly lower median concentrations in women with SGA infants compared with controls [14115 pg/ml (Interquartile range (IQR): 11510–16592 pg/ml) vs. 16582 pg/ml (IQR: 13658–20322 pg/ml)], it was not suitable as a screening test [35].

A systematic review and meta-analysis (32 studies; 175240 pregnancies) assessing the predictive utility of first trimester maternal serum PAPP-A concentrations for birth of an SGA infant, revealed poor predictive value with low positive (PLR) and negative (NLR) likelihood ratios for BW < 10th centile: PLR 1.96 (95% CI: 1.58–2.43), NLR 0.93 (95% CI: 0.89–0.98); BW < 5th centile: PLR 2.65 (95% CI: 2.35–2.99), NLR 0.85 (95% CI: 0.74–0.98) [36], suggesting that PAPP-A was not suitable as a standalone biomarker to predict SGA infants [19,36]. In another case–control study at 11–13 weeks of gestation, a combination of uterine artery pulsatility index (UtA-PI), maternal mean arterial pressure (MAP), and serum concentrations of PAPP-A, β hCG, PlGF, PP13, ADAM12 and fetal nuchal translucency thickness, yielded a detection rate of 73% and 46% for birth of a preterm and term SGA infant, respectively [37].

PP13 and AFP

PP13 is a glycan-binding protein mainly expressed in syncytiotrophoblast and secreted into the maternal circulation via exosomes or microvesicles [38]. Although an earlier observational study showed an association between low first trimester PP13 concentrations in maternal serum and FGR [39], subsequent studies [33,40] found limited predictive utility with no significant differences in median PP13 MoM levels in FGR-affected pregnancies even when combined with other first trimester screening markers such as PAPP-A [33] and ADAM12 [40]. Another study also showed that median PP13 concentrations in the first trimester of women with SGA infants (BW < 3rd, < 5th, and < 10th centiles) were not significantly lower than the control arms (0.978, 1.058, 1.051, and 1.083 MoM (controls) for each BW centiles, respectively) [41]. These findings were further corroborated in another study [42], which also failed to demonstrate the utility of PP13 for prediction of FGR [41]. In another study, median first trimester PP13 concentrations were significantly lower in FGR pregnancies compared with controls (86.6 vs. 132.5 pg/ml) but the overall sensitivity for the prediction of FGR was low at 33% at a specificity rate of 90% [43]. Two systematic reviews of first trimester serum PP13 in combination with maternal characteristics for the prediction of SGA infants reported low sensitivity of 32% (95% CI: 18–48%) [44] and 36% (95% CI: 33–41%) [45], respectively. The overall evidence thus far suggests that PP13 has limited clinical utility for predicting FGR.

In a study of 9715 singleton pregnancies (including 481 SGA infants with BW < 5th percentile), higher mean log₁₀ MoM value of maternal serum AFP at 19–24 weeks of gestation was seen in the SGA cohort. When AFP levels were combined with maternal factors, fetal biometry, and maternal PlGF concentrations, detection rates of 100%, 76%, and 38% were achieved for SGA infants delivered at <32, 32–36, and ≥37 weeks gestation, respectively [34]. The addition of UtA-PI measurement further improved detection rates of SGA infants to 78% at 32–36 weeks and 42% at >37 weeks, respectively [46]. Another retrospective study [47] showed that while elevated serum AFP concentrations (≥2.5 MoM) in the first trimester was associated with birth of an SGA infant, its predictive utility for SGA and FGR was low with an AUROC of <0.6 [47]. Similarly, other studies have also demonstrated that although third trimester AFP concentrations are significantly lower in women with SGA infants, the overall detection rate using this biomarker is low at 26%, and even when it is combined with maternal PlGF concentrations detection rates only modestly increase to 32% [48]. A recent meta-analysis (39 cohort studies; 93968 women) reported that the relative risk (RR) for birth of an SGA infant in women with elevated AFP concentrations was increased (RR: 2.02, 95% CI: 1.75–2.33) and this risk was higher when ultrasound evidence of SGA was present (RR: 5.28, 95% CI: 3.46–8.06) [49].

Inhibin A, activin A, and follistatin

Maternal serum concentrations of activin A, inhibin A, and the activin:follistatin ratio in the third trimester have been reported to be significantly increased in FGR pregnancies compared with controls [50]. However, in another study, there was no difference in activin A or inhibin A concentrations in normotensive women with SGA infants compared with controls [51]. A study by Miranda et al. [52] showed that although mean inhibin A concentrations were significantly higher in women with SGA infants, a multivariable integrative model of maternal characteristics, fetoplacental ultrasound, and maternal biochemical markers only modestly improved the detection of SGA/FGR cases at 32–36 weeks' gestation when compared with screening based on EFW centiles alone. Other studies [53] have also shown that the clinical utility of activin A, inhibin A, and follistatin as predictors for SGA/FGR is poor.

PGH, IGF-I, IGFBP, N-CAM, and FGF

PGH is mainly expressed by syncytiotrophoblast and stimulates gluconeogenesis and anabolic pathways to support the growing fetoplacental unit [54]. Earlier observational studies reported an association between low maternal serum PGH concentrations in the second and third trimesters and birth of an SGA infant [55,56]. However, in a later study [57], first trimester median maternal serum PGH concentrations in SGA pregnancies were not different to controls (0.95 MoM, 95% CI: 0.60–1.30 vs. 1.00 MoM, 95% CI: 0.70–1.30) and there was no association with BW centile.

Another study reported that although median maternal serum concentrations of IGF-I (61.8 ng/ml, IQR: 43.4–93.4 vs. 94.9 ng/ml, IQR: 56.7–131.2), IGFBP-1 (58.2 ng/ml, IQR: 39.8–84.9 vs. 81.4 ng/ml, IQR: 57.3–105.5), and IGFBP-3 (54.5 ng/ml, IQR: 45.6–61.5 vs. 55.4 ng/ml, IQR: 47.4–64.9) were significantly lower in women with SGA infants compared with controls [58], after multiple regression analyses and adjustment for maternal characteristics, these biomarkers were ultimately not useful for the prediction of SGA. Similarly, in another study, although a significant negative correlation between log IGFBP-1 and BW standard deviation score was noted, after adjusting for maternal body mass index, the relationship became nonsignificant [59]. IGFBP-4 is highly expressed by extravillous trophoblasts at the maternal–fetal interface [60] and circulating maternal IGFBP-4 concentrations in early pregnancy have been reported to be significantly higher in women with FGR infants (defined as BW < 5th centile) compared with controls [Odds ratio (OR) 22.3, (95% CI: 2.7–181.5)] with 93% positive predictive value (PPV) [60]. Current evidence, however, does not support the use of PGH, IGF-I, or IGFBP as reliable markers for the prenatal prediction of FGR [57–60].

A small observational study [61] reported an association between increased placental expression of N-CAM and FGF in cytotrophoblasts of pregnancies complicated by SGA (N-CAM immunoreactive cells median [range]: 26.0 [8–110] vs. 15.0 [8–29] (control group) and FGF: 45.0 [18–36] vs. 14.5 [5–26]). Another study showed that FGF-21 concentrations were significantly increased in amniotic fluid of SGA/FGR fetuses [62]. However, Hill et al. found that although maternal serum immunoreactive FGF-2 concentrations were lower in SGA pregnancies as compared with controls, the differences were not statistically significant [63]. The available evidence so far for the use of N-CAM and FGF for prediction of SGA/FGR is limited, and thus they should not be used in clinical practice until more data are available.

A systematic review and meta-analysis (103 studies; 432621 women) evaluating first trimester biomarkers (PAPP-A, β hCG, PlGF, and PP13) for the prediction of SGA reported low overall predictive accuracy [45]. Another review of AFP, β hCG, unconjugated estriol, PAPP-A, and inhibin A measured before 25 weeks gestation also reported poor predictive utility for SGA for all analytes [64]. However, high AFP and β hCG concentrations (>2 or >2.5 MoM) combined, appears to have better predictive utility for SGA infants (PLR: 6.18; 95% CI: 1.84–20.85) compared with unconjugated estriol, PAPP-A, and inhibin A [64,65]. Overall, however, the predictive value of AFP, β hCG, unconjugated estriol, PAPP-A, and inhibin A as biomarkers for SGA/FGR is low, either separately or in combination or incorporating maternal characteristics or ultrasound fetal biophysical variables [36,44,45,64–66].

SPINT1

SPINT1 is a circulating protein highly expressed by villous cytotrophoblasts. It is involved in the conversion of maternal spiral arteries into low pressure, high capacitance vessels by modulating trophoblast secretion of proteolytic enzymes (serine proteinases, metalloproteinases, and collagenases) that regulate transformation of spiral arteries in normal placentation [67]. *In vitro* and animal studies suggest that SPINT1 is modulated by hypoxia and decreased in FGR placentae. In a study of 2003 women [68] at 36 weeks' gestation, a strong association between low plasma SPINT1 concentrations and SGA (defined as <10th centile) was seen. Using a SPINT1 cutoff threshold of <0.63 MoM, the risk of delivering an SGA infant with BW <3rd, <5th, and <10th centile was 14.1%, 19.7%, and 28.2%, respectively [68]. A recent cohort study [69] found maternal plasma SPINT1 concentrations were significantly lower

at 20 weeks gestation in women who subsequently delivered an SGA infant; however, the AUROC was modest at 0.62 for BW <3rd centile and 0.56 for BW <19th centile, respectively. Murphy et al. [70] reported reduced plasma SPINT1 concentration in women with pre-eclampsia who subsequently delivered an SGA infant (median [IQR]: 18857 pg/ml [10782–29890] in SGA vs. 40168 pg/ml [22172342–75] in controls). Another study by Murphy et al. [67] found an association between elevated plasma serine protease inhibitor Kunitz type 2 (SPINT2), which is functionally related to SPINT1 in pregnancies complicated by pre-eclampsia and/or SGA. However, the evidence for SPINT1 as a suitable biomarker to predict SGA/FGR is limited, and more evidence is required to validate its clinical utility.

Angiogenic factors

Table 1 presents angiogenic biomarkers associated with SGA or FGR. Both vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) play an important role in facilitating angiogenesis in placenta and transforming spiral arteries into low resistance capacitance vessels [71–73]. Failure of remodeling of spiral arteries by extravillous trophoblast is seen in placentae from pregnancies complicated by pre-eclampsia or FGR and when there is an imbalance of proangiogenic (PlGF) and antiangiogenic factors [soluble fms-like tyrosine kinase 1 (sFlt-1)] [72]. Indeed the 2021 International Society for the Study of Hypertension in Pregnancy (ISSHP) [74] now includes angiogenic factors as a criterion to define uteroplacental dysfunction (placental abruption, PlGF <5th centile for gestational age or sFlt-1/PlGF ratio >38, FGR, abnormal umbilical artery Doppler waveform analysis or intrauterine fetal death).

PlGF, sFlt-1, and sFlt-1/PlGF ratio

In a recent publication, Gaccioli et al. [75] showed that although the sFlt-1/PlGF ratio was increased in both pre-eclampsia and FGR in both placenta and maternal serum, in pre-eclampsia the sFlt-1/PlGF ratio was strongly associated with placental sFlt-1 concentrations ($r=0.45$; $P<0.0001$) but not placental PlGF concentrations ($r=-0.17$; $P=0.16$). In FGR pregnancies, however, the sFlt-1/PlGF ratio was strongly associated with placental PlGF concentrations ($r=-0.35$; $P=0.02$) but not placental sFlt-1 concentrations ($r=0.04$; $P=0.81$) suggesting that in pre-eclampsia the elevated sFlt-1/PlGF ratio is primarily driven by increased placental sFlt-1, whereas in FGR, it is mainly due to decreased placental PlGF.

In a prospective cohort study [76], low plasma PlGF (<5th percentile for gestational age) identified FGR infants and significant placental dysfunction on histopathological examination with sensitivity of 98.2% (95% CI: 90.5–99.9) and PPV of 58.5% (95% CI: 47.9–68.6), respectively. Low maternal PlGF outperformed gestational age, fetal abdominal circumference, and umbilical artery Doppler resistance indices in predicting FGR secondary to placental dysfunction. In another study, high sFlt-1 expression was present in 28% of placental tissue from pregnancies complicated by SGA/FGR without pre-eclampsia and in this group, 90% had abnormal umbilical Doppler and lower mean BW [77].

The sFlt-1/PlGF ratio is inversely correlated with BW [78,79] and a high ratio is present in pregnancies complicated by FGR [80]. Furthermore, although the sFlt-1/PlGF ratio is elevated regardless of the gestation at which FGR is diagnosed, early-onset FGR is associated with higher ratios compared with late-onset FGR, suggesting a possible lesser degree of placental dysfunction in the latter group [78,81]. A high sFlt-1/PlGF ratio also predicts a shorter time to delivery interval, which in turn is even more strongly correlated with the magnitude of daily increase of the ratio [82]. A recent study by Mitlid-Mork et al. [83] showed that compared with controls, women with pregnancies complicated by placental syndromes (pre-eclampsia and/or FGR) median maternal concentrations of PlGF (104 vs. 165 pg/ml) were significantly lower while sFlt-1 (6927 vs. 4371 pg/ml) and the sFlt-1/PlGF ratio (73.1 vs. 28.4) were significantly higher. In another study that evaluated 120 cases of early-onset FGR, 75% had an sFlt-1/PlGF ratio ≥ 85 with an associated probability of delivery within 1 week of diagnosis of 36%. In contrast, a ratio of <85 was associated with a >70% probability of prolongation of pregnancy for >4 weeks [84]. A more recent study of early-onset FGR demonstrated a negative predictive value (NPV) (using an sFlt-1/PlGF cutoff threshold of 38) of 100% (95% CI: 0.92–1.00) for delivery within 2 weeks of diagnosis and a NPV of 50% for delivery within 1 week if the ratio was >85 [85]. Gaccioli et al. [86] reported that using an EFW of <10th centile for gestation and sFlt-1/PlGF ratio of >5.78 at 28 weeks resulted in a PLR of 41.1 (95% CI: 23.0–73.6) and PPV of 21.3% (95% CI: 11.6–35.8) for preterm birth of an SGA infant. Using a higher threshold sFlt-1/PlGF ratio of >38 at 36 weeks resulted in a PLR of 17.5 (95% CI: 11.8–25.9) for subsequent birth of an SGA infant associated with either maternal pre-eclampsia or perinatal morbidity or mortality [86]. Other observational studies have also reported similar associations between a high sFlt-1/PlGF ratio with SGA/FGR and a shorter duration to delivery interval [87,88]. A recent systematic review and meta-analysis (33 studies; 9426 women) showed that while PlGF, sFlt-1, and the sFlt-1/PlGF ratio showed promise for the prediction of adverse maternal and perinatal outcomes including SGA/FGR and time to delivery, PlGF was equivalent to the sFlt-1/PlGF ratio for predictive utility [89].

In a prospective study of 3953 singleton pregnancies at 35–37 weeks of gestation, Valino et al. showed that prediction of SGA (detection rate: 62.8%) was best achieved by maternal serum PlGF, ultrasound EFW, and UtA-PI [90]. However, compared with maternal serum PlGF, sFlt-1 does not provide significant independent prediction of SGA [90,91]. Another study by Valino et al. that screened 8268 singleton pregnancies at an earlier gestation of 30–34 weeks demonstrated that prediction of SGA using EFW, PlGF, sFlt-1, UtA-PI, umbilical artery pulsatility index, and middle cerebral artery pulsatility index resulted in a detection rates of 88% and 51% for birth of a preterm and term SGA infant, respectively [92].

A recent systematic review and meta-analysis (eight studies; 5450 women) [93] evaluating the diagnostic capacity of the sFlt-1/PlGF ratio for FGR showed that a ratio of >33 was predictive for FGR, [Sensitivity 63% (95% CI: 54–71), specificity 84%, (95% CI: 83–85)] but had a low PLR of 3.55 (95% CI: 1.98–6.34). A higher ratio of ≥ 85 resulted in higher sensitivity 79% (95% CI: 66–89) but with similarly low PLR of 3.23 (95% CI: 0.94–11.11). Given the clear correlation of elevated sFlt-1 and sFlt-1/PlGF ratio with placental dysfunction and SGA/FGR infants both in early [94–96] and late gestation [86,97,98], there is increasing evidence supporting their use together with maternal characteristics and fetal biophysical ultrasound parameters in screening tests for SGA/FGR [22,24,99,100]. A high sFlt-1/PlGF ratio also appears to be predictive of adverse neonatal outcomes (admission to neonatal intensive care unit, severe respiratory disorders, and necrotizing enterocolitis) in SGA neonates [101,102]. There is some evidence however that fetal sex may also influence the sFlt-1/PlGF ratio. In a recent study, normotensive women with male fetuses had significantly higher sFlt-1 concentrations and sFlt-1/PlGF ratio compared with normotensive women with a female fetus. However, this difference was not observed in pregnant women with hypertensive disorders [103]. In another study, the sFlt-1/SPINT1 ratio was significantly raised in pregnancies with pre-eclampsia and/or SGA with median ratios (IQR) of 1.4 [0.44–2.54] and 0.82 [0.28–1.39] for BW $<3^{\text{rd}}$ and 3^{rd} – 10^{th} centiles, respectively [70].

Another retrospective cohort study [104] reported that a low sFlt-1/PlGF ratio of <23 ruled out early-onset pre-eclampsia between 24- and 33^{+6} -weeks' gestation (NPV of 100%), while a ratio of >45 in combination with N-terminal-pro b-type natriuretic peptide (NT-proBNP) concentrations of >174 pg/ml increased the PPV from 49.5% to 86% (95% CI: 79.2–92.6). The median concentrations of NT-proBNP were significantly higher in women with pre-eclampsia (156.5 pg/ml, IQR: [78–343]) compared with those with isolated FGR (48 pg/ml, IQR: [24–59]) and normal pregnancy (47.5 pg/ml, IQR: [25–89]) [105].

In twin pregnancies, the sFlt-1/PlGF ratio measured in the second trimester is associated with increased odds for FGR (OR: 39.6, 95% CI: 6.31–248.17) [106]. However, as a standalone marker, PlGF does not appear to be sufficiently robust (sensitivity 27%) for the prediction of FGR for women with multiple pregnancy [107].

Soluble endoglin

Another placenta-derived antiangiogenic factor associated with placental dysfunction is soluble endoglin (sEng). sEng is a soluble transforming growth factor- β (TGF- β) coreceptor, which has been shown to be elevated in sera of women with pre-eclampsia and FGR [108–110]. An early small observational study (44 women) reported positive correlation between sEng and sFlt-1 concentrations (Pearson 0.653; $P<0.05$) with significantly higher sEng concentrations in FGR pregnancies compared with controls. However, concentrations of sEng were lower in FGR compared with pre-eclampsia pregnancies [111]. More recent study showed that sEng is strongly correlated with sFlt-1/PlGF ratio with higher concentrations observed in FGR (OR: 2.28, 95% CI: 1.55–3.4 and 2.38, 95% CI: 1.64–3.44 for sEng and sFlt-1/PlGF, respectively) [112]. Another study, however, did not find any significant association between maternal concentrations of sEng and time of delivery in pregnancies complicated by FGR [113]. The current evidence for the utility of sEng for the prediction of SGA/FGR is limited.

Cell-free fetal DNA

Circulating cell-free fetal DNA (cffDNA) is used for aneuploidy screening, determination of fetal red cell antigen status, fetal sex, and screening for single-gene disorders [114–116]. cffDNA concentrations increase with gestational age and significantly higher levels are seen pregnancies complicated by placental dysfunction [117,121]. The data however from pregnancies complicated by FGR are conflicting, with some studies suggesting an increase [117–119] in cffDNA concentrations while others showing a decrease [120–122] compared with controls.

Lower median cffDNA fractions were observed only in women with early but not late FGR [121,122], suggesting that the lower fetal fraction could be the consequence of a smaller placental mass. However, other studies report that cffDNA concentrations are increased in pregnancies complicated by FGR with abnormal umbilical artery Doppler velocimetry raising the possibility that fetal DNA release is associated more with chronic fetal hypoxia than with fetal size [123]. Caramelli et al. [118] reported a more than twofold increase in cffDNA concentration in pregnancies

Table 2 Circulating miRNAs in FGR

miRNA type	Expression in FGR/SGA	References
miR-210	Increased	[140]
miR-21	Increased	[140]
miR-424	Increased	[140]
miR-199a	Increased	[140]
miR-20b	Decreased	[137]
miR-942-5p	Decreased	[137]
miR-324-3p	Decreased	[137]
miR-127-3p	Decreased	[137]
miR-223-5p	Decreased	[137]
miR-17-5p	Decreased	[134]
miR-146a-5p	Decreased	[134]
miR-574-3p	Decreased	[134]
miR-221-3p	Decreased	[134]
miR-374a-5p	Increased	[136]
Let-7d-5p	Increased	[136]
miR-191-5p	Increased	[136]
miR-107	Decreased	[136]
miR-30e-5p	Decreased	[136]
miR-4454+7975	Decreased	[136]
miR-27b-3p	Increased	[138]
miR-16-5p	Increased	[138]
miR-103-3p	Increased before 32 weeks of gestation Decreased between 32 and 37 weeks of gestation	[138]
miR-107-3p	Increased before 32 weeks of gestation Decreased between 32 and 37 weeks of gestation	[138]
miR-346	Increased	[139]
miR-582-3p	Increased	[139]
miR-16-5p	Increased	[135]
miR-20a-5p	Increased	[135]
miR-146a-5p	Increased	[135]
miR-155-5p	Increased	[135]
miR-181a-5p	Increased	[135]
miR-195-5p	Increased	[135]
miR-145-5p	Increased	[135]
miR-342-3p	Increased	[135]
miR-574-3p	Increased	[135]
miR-1-3p	Increased	[135]
miR-20b-5p	Increased	[135]
miR-126-3p	Increased	[135]
miR-130b-3p	Increased	[135]
miR-499a-5p	Increased	[135]

complicated by FGR and abnormal uterine artery Doppler waveforms when compared with controls [117]. In another analysis, Smid et al. [119] showed that maternal plasma fetal DNA concentration in pregnancies complicated by FGR, median cfDNA concentrations were higher compared with controls (308.1 vs. 74.8 g.e./ml).

Poon et al. [124] measured plasma cfDNA from 1949 singleton pregnancies at 11–13 weeks of gestation and found that although concentrations were inversely related to maternal weight and UtA-PI, compared with controls, there was no difference with pregnancies complicated by SGA/FGR [124]. Other observational studies have also reported the lack of difference between cfDNA concentrations in FGR and control cohorts [125].

In a retrospective cohort study of 4317 singleton pregnancies [120], the fetal fraction was inversely correlated with MAP, UtA-PI, and positively associated with maternal PAPP-A and PlGF concentrations. A lower fetal fraction was associated with a higher risk of preterm FGR. Given the limited and inconsistent data regarding the relationship between maternal cfDNA concentrations and SGA/FGR, its utility as a reliable predictive marker remains unclear and further research is required [126–128].

Table 3 Essential miRNAs in pre-eclampsia with or without FGR

Pre-eclampsia with FGR	Pre-eclampsia without FGR
miR-210	miR-144
miR-17	miR-152
miR-16	miR-182
miR-21	miR-29a
miR-103	miR-29b
miR-181a	miR-24
miR-130b-3p	miR-26a
miR-155	miR-299
miR-181a	miR-342-3p
miR-20a	miR-215
miR-20b	miR-650
miR-126	miR-423-5p
miR-519a	miR-629-5p
miR-141	miR-18a
miR-194	miR-195
miR-520a-5p	miR-376c
miR-525	
miR-146a-5p	
miR-221-3p	
miR-574-3p	
miR-346	
miR-582-3p	
miR-126	

MicroRNAs

MicroRNAs (miRNAs) are small nonprotein-coding, single-stranded RNA molecules of up to 19–25 nucleotides. They influence post-transcriptional gene expression and help regulate cell development, differentiation, proliferation, and apoptosis [129,130]. Because they are relatively stable and resistant to degradation by temperature and pH changes circulating miRNAs have potential as biomarkers for the prediction of adverse placenta-related outcomes [131].

The placenta expresses many generic as well as placenta-specific miRNAs, which influence angiogenesis as well as trophoblast differentiation, proliferation, invasion, and migration [132]. Placentally derived miRNAs are exported from syncytiotrophoblast cells into the maternal circulation via exosomes [133]. Table 2 [134–140] details currently known circulating miRNAs associated with FGR.

miR-210, a hypoxia-induced miRNA is expressed in different subtypes of placental trophoblasts and its deficiency is causally related to pre-eclampsia and placental adaptation to maternal hypoxia [141–143]. In pregnancies complicated by FGR, decreased expression of some placenta-specific miRNAs (miR-21, miR-16, miR-516b, miR-518b, miR-520h, miR-526b, miR-515-5p, miR-519d, and miR-1323) [144,145] have been reported. Table 3 lists the essential miRNAs in pre-eclampsia with or without FGR. miR-16 (OR: 4.13, 95% CI: 1.42–12.05) and miR-21 (OR: 2.43, 95% CI: 0.93–6.37), in particular, are strongly associated with birth of an SGA infant [144]. However, in another study, although four specific miRNAs (has – miR-518b, has – miR-1323, has – miR-520h, and has – miR-519d) were confirmed as FGR-associated, placenta-specific miRNAs, there was no difference in maternal plasma concentrations between FGR and uncomplicated pregnancies [145].

Whitehead et al. [140] found three- to sixfold increased concentrations of miR-210, miR-424, miR-21, miR-199a, and miR-20b in women with severe preterm FGR, which correlated with ultrasound Doppler velocimetry. On the other hand, higher circulating maternal serum concentrations of miR-20b-5p, miR-324-3p, miR-223-5p, and miR-127-3p in the second trimester were associated with lower odds of having an SGA infant [137]. Hromadnikova et al. [146] showed that in pregnancies complicated by FGR, significantly decreased concentrations of seven miRNAs were seen: miR-100-5p, miR-125b-5p, miR-199a-5p, miR-17-5p, miR-146a-5p, miR-221-3p, and miR-574-3p. Kim et al. [136] identified two unique miRNAs (hsa-miR374a-5p and hsa-let-7d-5p) that were expressed in significantly higher concentrations in plasma of women with SGA infants, indicating their potential for early prediction of SGA/FGR. Another recent study by Hromadnikova et al. [135] assessed the association of

29 cardiovascular disease-associated miRNAs in first trimester maternal blood samples and found that concentrations of six miRNAs were significantly increased in SGA/FGR pregnancies: miR-16-5p, miR-20a-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, and miR-195-5p. A combination of four miRNAs (miR-1-3p, miR-20a-5p, miR-146a-5p, and miR-181a-5p) detected almost 76% of SGA infants, while a combination of seven miRNAs (miR-16-5p, miR-20a-5p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-342-3p, and miR-574-3p) detected approximately 43% of FGR infants [135].

Tagliaferri et al. [138] evaluated a group of hypoxia-regulated miRNAs and found elevated circulating concentrations of miR-16-5p, miR-103-3p, miR-107-3p, and miR-27b-3p in early FGR (<32 weeks of gestation), while reduced concentrations of miR-103-3p and miR-107-3p were noted in late FGR (measured between 32 and 37 weeks of gestation). Kim et al. [136] assessed 50 miRNAs profiles across gestation in SGA (defined as BW < 5th percentile) pregnancies and found significantly increased maternal plasma concentrations of miR-374a-5p, let-7d-5p, and miR-191-5p and decreased concentrations of miR-107, miR-30e-5p and miR-4454+7975. Of these miRNAs, miR-374a-5p and let-7d-5p showed reasonable predictive value for SGA when evaluated individually (AUROC: 0.71, 95% CI: 0.56–0.86 and 0.74, 95% CI: 0.55–0.93), respectively, with improvement when both were combined (AUROC 0.772, 95% CI: 0.601–0.943) [136]. Although there are some specific miRNAs that are associated with placental dysfunction, which may have a role to play for either the prediction or diagnosis of FGR, their utility thus far, as reliable clinical biomarkers is uncertain.

Conclusions

Early prenatal identification of infants at high risk of SGA/FGR or adverse perinatal outcomes such as stillbirth, neonatal morbidity, and mortality is important because it potentially allows decisions regarding intensity of antenatal surveillance, timing of birth, model of maternity care, parental counselling, and co-ordination of neonatal resources to be made. Thus, the attraction of a simple and acceptable screening test early in pregnancy is obvious. However, there are several circulating biomarkers that are clearly associated with adverse outcomes, none have yet, either alone or in combination, been shown to be sufficiently reliable to be used in clinical practice [147]. Some, such as PlGF [148] and sFlt-1 [149] show the most promise but require further validation to determine their screening performance. More importantly, however, it is important to determine if a policy of screening for disorders related to placental dysfunction results in improvements in clinical outcomes.

Data Availability

All data are included within the main article.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Open Access

Open access for the present article was enabled by the participation of University of Queensland in an all-inclusive *Read & Publish* agreement with Portland Press and the Biochemical Society under a transformative agreement with CAUL.

CRedit Author Contribution

Jesrine Hong: Conceptualization, Data curation, Writing—original draft, Writing—review & editing. **Sailesh Kumar:** Conceptualization, Resources, Supervision, Writing—review & editing.

Abbreviations

β-hCG, beta-human chorionic gonadotrophin; ADAM12, a disintegrin and metalloprotease 12; AFP, alpha-fetoprotein; AUROC, area under receiver-operating curve; BW, birthweight; cffDNA, cell-free fetal DNA; EFW, estimated fetal weight; FGF, fibroblast growth factor; FGR, fetal growth restriction; FPR, false-positive rate; IGF-I, insulin-like growth factor-I; IGFBP-1, -3, -4, IGF-binding protein-1, -3, -4; IQR, Interquartile range; LBW, low birth weight; MAP, maternal mean arterial pressure; MoM, multiples of median; N-CAM, neural cell adhesion molecule; NLR, negative likelihood ratio; NPV, negative predictive value; NT-proBNP, N-terminal-pro b-type natriuretic peptide; OR, odds ratio; PAPP-A, pregnancy-associated plasma protein-A; PGH, placental growth hormone; PlGF, placental growth factor; PLR, positive likelihood ratio; PP13, placental protein 13; PPV, positive predictive value; RR, relative risk; sEng, soluble endoglin; sFlt-1, soluble fms-like tyrosine kinase 1; SGA, small for gestational age; SPINT1, serine protease inhibitor Kunitz type 1; TGF-β, transforming growth factor-beta; UtA-PI, uterine artery pulsatility index; VEGF, vascular endothelial growth factor.

References

- World Health Organization (1995) *WHO Expert Committee on Physical Status : the Use and Interpretation of Anthropometry* (1993 : Geneva, Switzerland) & World Health Organization. Report, WHO, <https://apps.who.int/iris/handle/10665/37003>
- Group WHOMGRS (2006) WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr. Suppl.* **450**, 76–85
- de Onis, M., Onyango, A., Borghi, E., Siyam, A., Blössner, M., Lutter, C. et al. (2012) Worldwide implementation of the WHO Child Growth Standards. *Public Health Nutr.* **15**, 1603–1610, <https://doi.org/10.1017/S136898001200105X>
- UNICEF (2019) UNICEF-WHO low birthweight estimates: levels and trends 2000–2015. [https://data.unicef.org/resources/unicef-who-low-birthweight-estimates-levels-and-trends-2000-2015/Accessed 13 July 2022](https://data.unicef.org/resources/unicef-who-low-birthweight-estimates-levels-and-trends-2000-2015/Accessed%2013%20July%2022)
- Katz, J., Lee, A.C., Kozuki, N., Lawn, J.E., Cousens, S., Blencowe, H. et al. (2013) Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. *Lancet* **382**, 417–425, [https://doi.org/10.1016/S0140-6736\(13\)60993-9](https://doi.org/10.1016/S0140-6736(13)60993-9)
- de Mendonca, E., de Lima Macena, M., Bueno, N.B., de Oliveira, A.C.M. and Mello, C.S. (2020) Premature birth, low birth weight, small for gestational age and chronic non-communicable diseases in adult life: a systematic review with meta-analysis. *Early Hum. Dev.* **149**, 105154, <https://doi.org/10.1016/j.earlhumdev.2020.105154>
- Hocquette, A., Durox, M., Wood, R., Klungsøyr, K., Szamotulska, K. and Berrut, S. (2021) International versus national growth charts for identifying small and large-for-gestational age newborns: a population-based study in 15 European countries. *Lancet Reg. Health Eur.* **8**, 100167, <https://doi.org/10.1016/j.lanepe.2021.100167>
- Hughes, M.M., Black, R.E. and Katz, J. (2017) 2500-g low birth weight cutoff: history and implications for future research and policy. *Matern. Child Health J.* **21**, 283–289, <https://doi.org/10.1007/s10995-016-2131-9>
- Ventolini, G. and Neiger, R. (2006) Placental dysfunction: pathophysiology and clinical considerations. *J. Obstet. Gynaecol.* **26**, 728–730, <https://doi.org/10.1080/01443610600955685>
- Regnault, T.R., Galan, H.L., Parker, T.A. and Anthony, R.V. (2002) Placental development in normal and compromised pregnancies— a review. *Placenta* **23**, S119–S129, <https://doi.org/10.1053/plac.2002.0792>
- Brosens, I., Pijnenborg, R., Vercruysse, L. and Romero, R. (2011) The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. *Am. J. Obstet. Gynecol.* **204**, 193–201, <https://doi.org/10.1016/j.ajog.2010.08.009>
- Aplin, J.D., Myers, J.E., Timms, K. and Westwood, M. (2020) Tracking placental development in health and disease. *Nat. Rev. Endocrinol.* **16**, 479–494, <https://doi.org/10.1038/s41574-020-0372-6>
- Gibbs, I., Leavey, K., Benton, S.J., Grynspan, D., Bainbridge, S.A. and Cox, B.J. (2019) Placental transcriptional and histologic subtypes of normotensive fetal growth restriction are comparable to preeclampsia. *Am. J. Obstet. Gynecol.* **220**, 110e111–110e121, <https://doi.org/10.1016/j.ajog.2018.10.003>
- Kingdom, J.C. and Kaufmann, P. (1997) Oxygen and placental villous development: origins of fetal hypoxia. *Placenta* **18**, 613–621, discussion 623–616, [https://doi.org/10.1016/S0143-4004\(97\)90000-X](https://doi.org/10.1016/S0143-4004(97)90000-X)
- Gude, N.M., Roberts, C.T., Kalonis, B. and King, R.G. (2004) Growth and function of the normal human placenta. *Thromb. Res.* **114**, 397–407, <https://doi.org/10.1016/j.thromres.2004.06.038>
- Burton, G.J. and Jauniaux, E. (2018) Pathophysiology of placental-derived fetal growth restriction. *Am. J. Obstet. Gynecol.* **218**, S745–S761, <https://doi.org/10.1016/j.ajog.2017.11.577>
- Bendix, I., Miller, S.L. and Winterhager, E. (2020) Editorial: Causes and consequences of intrauterine growth restriction. *Front. Endocrinol. (Lausanne)* **11**, 205, <https://doi.org/10.3389/fendo.2020.00205>
- Maynard, S.E., Min, J.Y., Merchan, J., Lim, K., J., Li, Mondal, S. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J. Clin. Invest.* **111**, 649–658, <https://doi.org/10.1172/JCI17189>
- Dugoff, L., Hobbins, J.C., Malone, F.D., Porter, T.F., Luthy, D., Comstock, C.H. et al. (2004) First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). *Am. J. Obstet. Gynecol.* **191**, 1446–1451, <https://doi.org/10.1016/j.ajog.2004.06.052>
- Gaccioli, F., Aye, I., Sovio, U., Charnock-Jones, D.S. and Smith, G.C.S. (2018) Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. *Am. J. Obstet. Gynecol.* **218**, S725–S737, <https://doi.org/10.1016/j.ajog.2017.12.002>
- Sibley, C.P. (2017) Treating the dysfunctional placenta. *J. Endocrinol.* **234**, R81–R97, <https://doi.org/10.1530/JOE-17-0185>
- Heazell, A.E., Hayes, D.J., Whitworth, M., Takwoingi, Y., Bayliss, S.E. and Davenport, C. (2019) Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. *Cochrane Database Syst. Rev.* **5**, CD012245, <https://doi.org/10.1002/14651858.CD012245.pub2>
- de Bernis, L., Kinney, M.V., Stones, W., Hoope-Bender, P.T., Vivio, D., Leisher, S.H. et al. (2016) Stillbirths: ending preventable deaths by 2030. *Lancet North Am. Ed.* **387**, 703–716, [https://doi.org/10.1016/S0140-6736\(15\)00954-X](https://doi.org/10.1016/S0140-6736(15)00954-X)
- Ruchob, R., Rutherford, J.N. and Bell, A.F. (2018) A systematic review of placental biomarkers predicting small-for-gestational-age neonates. *Biol. Res. Nurs.* **20**, 272–283, <https://doi.org/10.1177/1099800418760997>
- Weinhold, B. (2006) Epigenetics: the science of change. *Environ. Health Perspect.* **114**, A160–A167, <https://doi.org/10.1289/ehp.114-a160>
- Henikoff, S. and Gready, J.M. (2016) Epigenetics, cellular memory and gene regulation. *Curr. Biol.* **26**, R644–R648, <https://doi.org/10.1016/j.cub.2016.06.011>
- Apicella, C., Ruano, C.S.M., Mehats, C., Miralles, F. and Vaiman, D. (2019) The role of epigenetics in placental development and the etiology of preeclampsia. *Int. J. Mol. Sci.* **20**, 2837, <https://doi.org/10.3390/ijms20112837>
- Nelissen, E.C., van Montfort, A.P., Dumoulin, J.C. and Evers, J.L. (2011) Epigenetics and the placenta. *Hum. Reprod. Update* **17**, 397–417, <https://doi.org/10.1093/humupd/dmq052>

- 29 Poon, L.C., Chelemen, T., Granvillano, O., Pandeva, I. and Nicolaides, K.H. (2008) First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. *Obstet. Gynecol.* **112**, 1082–1090, <https://doi.org/10.1097/AOG.0b013e318188d6f9>
- 30 Poon, L.C., Karagiannis, G., Staboulidou, I., Shafiei, A. and Nicolaides, K.H. (2011) Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates. *Prenat. Diagn.* **31**, 58–65, <https://doi.org/10.1002/pd.2520>
- 31 Cowans, N.J. and Spencer, K. (2007) First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. *Prenat. Diagn.* **27**, 264–271, <https://doi.org/10.1002/pd.1665>
- 32 Pihl, K., Larsen, T., Krebs, L. and Christiansen, M. (2008) First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. *Prenat. Diagn.* **28**, 1131–1135, <https://doi.org/10.1002/pd.2141>
- 33 Stamatopoulou, A., Cowans, N.J., Matwejew, E., von Kaisenberg, C. and Spencer, K. (2011) Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes. *Hypertens. Pregnancy* **30**, 384–395, <https://doi.org/10.3109/10641955.2010.484081>
- 34 Lesmes, C., Gallo, D.M., Gonzalez, R., Poon, L.C. and Nicolaides, K.H. (2015) Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19–24 weeks. *Ultrasound Obstet. Gynecol.* **46**, 341–349, <https://doi.org/10.1002/uog.14899>
- 35 Andres, F., Wong, G.P., Walker, S.P., MacDonald, T.M., Keenan, E., Cannon, P. et al. (2022) A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks' gestation in pregnancies destined to deliver small for gestational age infants. *Placenta* **117**, 1–4, <https://doi.org/10.1016/j.placenta.2021.11.001>
- 36 Morris, R.K., Bilagi, A., Devani, P. and Kilby, M.D. (2017) Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. *Prenat. Diagn.* **37**, 253–265, <https://doi.org/10.1002/pd.5001>
- 37 Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D. and Nicolaides, K.H. (2011) Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. *Fetal Diagn. Ther.* **29**, 148–154, <https://doi.org/10.1159/000321694>
- 38 Gadde, R., Cd, D. and Sheela, S.R. (2018) Placental protein 13: an important biological protein in preeclampsia. *J Circ Biomark* **7**, 1849454418786159, <https://doi.org/10.1177/1849454418786159>
- 39 Burger, O., Pick, E., Zwickel, J., Klayman, M., Meiri, H., Slotky, R. et al. (2004) Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. *Placenta* **25**, 608–622, <https://doi.org/10.1016/j.placenta.2003.12.009>
- 40 Deurloo, K.L., Linskens, I.H., Heymans, M.W., Heijboer, A.C., Blankenstein, M.A. and van Vugt, J.M. (2013) ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome. *Clin. Chem. Lab. Med.* **51**, 1279–1284, <https://doi.org/10.1515/ccbm-2012-0566>
- 41 Cowans, N.J., Spencer, K. and Meiri, H. (2008) First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. *Prenat. Diagn.* **28**, 121–125, <https://doi.org/10.1002/pd.1921>
- 42 Seravalli, V., Grimpel, Y.I., Meiri, H., Blitzler, M. and Baschat, A.A. (2016) Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome. *J. Perinat. Med.* **44**, 543–549, <https://doi.org/10.1515/jpm-2015-0324>
- 43 Chafetz, I., Kuhnreich, I., Sammar, M., Tal, Y., Gibor, Y., Meiri, H. et al. (2007) First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. *Am. J. Obstet. Gynecol.* **197**, 35e31–35e37, <https://doi.org/10.1016/j.ajog.2007.02.025>
- 44 Schnerer, F.J., Nassar, N., Khambalia, A.Z., Tasevski, V., Guilbert, C., Ashton, A.W. et al. (2012) First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review. *Placenta* **33**, 735–740, <https://doi.org/10.1016/j.placenta.2012.05.012>
- 45 Zhong, Y., Zhu, F. and Ding, Y. (2015) Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. *BMC Pregnancy Childbirth* **15**, 191, <https://doi.org/10.1186/s12884-015-0608-y>
- 46 Poon, L.C., Lesmes, C., Gallo, D.M., Akolekar, R. and Nicolaides, K.H. (2015) Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19–24 weeks. *Ultrasound Obstet. Gynecol.* **46**, 437–445, <https://doi.org/10.1002/uog.14904>
- 47 Hu, J., Zhang, J., He, G., Zhu, S., Tang, X., Su, J. et al. (2020) First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases. *BMC Pregnancy Childbirth* **20**, 104, <https://doi.org/10.1186/s12884-020-2789-2>
- 48 Bakalis, S., Peeva, G., Gonzalez, R., Poon, L.C. and Nicolaides, K.H. (2015) Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30–34 weeks. *Ultrasound Obstet. Gynecol.* **46**, 446–451, <https://doi.org/10.1002/uog.14863>
- 49 Goto, E. (2021) Association of high maternal blood alpha-fetoprotein level with risk of delivering small for gestational age: a meta-analysis. *Pediatr. Res.* **89**, 1742–1750, <https://doi.org/10.1038/s41390-020-01124-8>
- 50 Bobrow, C.S., Holmes, R.P., Muttukrishna, S., Mohan, A., Groome, N., Murphy, D.J. et al. (2002) Maternal serum activin A, inhibin A, and follistatin in pregnancies with appropriately grown and small-for-gestational-age fetuses classified by umbilical artery Doppler ultrasound. *Am. J. Obstet. Gynecol.* **186**, 283–287, <https://doi.org/10.1067/mob.2002.119777>
- 51 Keelan, J.A., Taylor, R., Schellenberg, J.C., Groome, N.P., Mitchell, M.D. and North, R.A. (2002) Serum activin A, inhibin A, and follistatin concentrations in preeclampsia or small for gestational age pregnancies. *Obstet. Gynecol.* **99**, 267–274
- 52 Miranda, J., Rodriguez-Lopez, M., Triunfo, S., Sairanen, M., Kouru, H., Parra-Saavedra, M. et al. (2017) Prediction of fetal growth restriction using estimated fetal weight vs a combined screening model in the third trimester. *Ultrasound Obstet. Gynecol.* **50**, 603–611, <https://doi.org/10.1002/uog.17393>
- 53 Kim, S.M., Yun, H.G., Kim, R.Y., Chung, Y.H., Cheon, J.Y., Wie, J.H. et al. (2017) Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia. *Taiwan J. Obstet. Gynecol.* **56**, 801–805, <https://doi.org/10.1016/j.tjog.2017.10.017>
- 54 Fuglsang, J. and Ovesen, P. (2006) Aspects of placental growth hormone physiology. *Growth Horm. IGF Res.* **16**, 67–85, <https://doi.org/10.1016/j.ghir.2006.03.010>
- 55 Mirlesse, V., Frankenke, F., Alsat, E., Poncelet, M., Hennen, G. and Evain-Brion, D. (1993) Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. *Pediatr. Res.* **34**, 439–442, <https://doi.org/10.1203/00006450-199310000-00011>

- 56 McIntyre, H.D., Serek, R., Crane, D.I., Veveris-Lowe, T., Parry, A., Johnson, S. et al. (2000) Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth-retarded, and diabetic pregnancies: correlations with fetal growth. *J. Clin. Endocrinol. Metab.* **85**, 1143–1150
- 57 Sifakis, S., Akolekar, R., Kappou, D., Mantas, N. and Nicolaides, K.H. (2012) Maternal serum placental growth hormone at 11–13 weeks' gestation in pregnancies delivering small for gestational age neonates. *J. Matern. Fetal Neonatal Med.* **25**, 1796–1799, <https://doi.org/10.3109/14767058.2012.663834>
- 58 Sifakis, S., Akolekar, R., Kappou, D., Mantas, N. and Nicolaides, K.H. (2012) Maternal serum insulin-like growth factor (IGF-I) and binding proteins IGFBP-1 and IGFBP-3 at 11–13 weeks' gestation in pregnancies delivering small for gestational age neonates. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **161**, 30–33, <https://doi.org/10.1016/j.ejogrb.2011.12.022>
- 59 Holmes, R.P., Holly, J.M. and Soothill, P.W. (2000) Maternal insulin-like growth factor binding protein-1, body mass index, and fetal growth. *Arch. Dis. Child. Fetal Neonatal Ed.* **82**, F113–F117, <https://doi.org/10.1136/fn.82.2.F113>
- 60 Qiu, Q., Bell, M., Lu, X., Yan, X., Rodger, M., Walker, M. et al. (2012) Significance of IGFBP-4 in the development of fetal growth restriction. *J. Clin. Endocrinol. Metab.* **97**, E1429–E1439, <https://doi.org/10.1210/jc.2011-2511>
- 61 Ozkan, S., Vural, B., Dalcik, C., Tas, A. and Dalcik, H. (2008) Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic and neural cell adhesion molecule in pregnancies with small for gestational age fetuses. *J. Perinatol.* **28**, 468–474, <https://doi.org/10.1038/jp.2008.27>
- 62 Vrachnis, N., Argyridis, S., Vrachnis, D., Antonakopoulos, N., Valsamakis, G., Iavazzo, C. et al. (2021) Increased fibroblast growth factor 21 (FGF21) concentration in early second trimester amniotic fluid and its association with fetal growth. *Metabolites* **11**, 581, <https://doi.org/10.3390/metabo11090581>
- 63 Hill, D.J., Tevaarwerk, G.J., Arany, E., Kilkenny, D., Gregory, M., Langford, K.S. et al. (1995) Fibroblast growth factor-2 (FGF-2) is present in maternal and cord serum, and in the mother is associated with a binding protein immunologically related to the FGF receptor-1. *J. Clin. Endocrinol. Metab.* **80**, 1822–1831
- 64 Morris, R.K., Cnossen, J.S., Langejans, M., Robson, S.C., Kleijnen, J., Riet, G.T. et al. (2008) Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. *BMC Pregnancy Childbirth* **8**, 33, <https://doi.org/10.1186/1471-2393-8-33>
- 65 Hui, D., Okun, N., Murphy, K., Kingdom, J., Ulerik, E. and Shah, P.S. (2012) Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. *J. Obstet. Gynaecol. Can.* **34**, 142–153, [https://doi.org/10.1016/S1701-2163\(16\)35157-X](https://doi.org/10.1016/S1701-2163(16)35157-X)
- 66 Goto, E. (2017) Maternal blood biomarkers of placentation to predict low-birth-weight newborns: a meta-analysis. *J. Obstet. Gynaecol. Can.* **39**, 635–644, <https://doi.org/10.1016/j.jogc.2017.03.099>
- 67 Murphy, C.N., Walker, S.P., MacDonald, T.M., Keenan, E., Hannan, N.J., Wlodek, M.E. et al. (2021) Elevated circulating and placental SPINT2 is associated with placental dysfunction. *Int. J. Mol. Sci.* **22**, 7467, <https://doi.org/10.3390/ijms22147467>
- 68 Kaitu'u-Lino, T.J., MacDonald, T.M., Cannon, P., Nguyen, T.V., Hiscock, R.J., Haan, N. et al. (2020) Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. *Nat. Commun.* **11**, 2411, <https://doi.org/10.1038/s41467-020-16346-x>
- 69 Tong, S., Walker, S.P., Keenan, E., MacDonald, T.M., Taylor, R., McCowan, L.M.E. et al. (2022) Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies. *Am. J. Obstet. Gynecol. MFM* **4**, 100618, <https://doi.org/10.1016/j.ajogmf.2022.100618>
- 70 Murphy, C.N., Cluver, C.A., Walker, S.P., Keenan, E., Hastie, R., MacDonald, T.M. et al. (2022) Circulating SPINT1 is reduced in a preeclamptic cohort with co-existing fetal growth restriction. *J. Clin. Med.* **11**, 901, <https://doi.org/10.3390/jcm11040901>
- 71 Pereira, R.D., De Long, N.E., Wang, R.C., Yazdi, F.T., Holloway, A.C. and Raha, S. (2015) Angiogenesis in the placenta: the role of reactive oxygen species signaling. *Biomed. Res. Int.* **2015**, 814543, <https://doi.org/10.1155/2015/814543>
- 72 Rana, S., Burke, S.D. and Karumanchi, S.A. (2022) Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. *Am. J. Obstet. Gynecol.* **226**, S1019–S1034, <https://doi.org/10.1016/j.ajog.2020.10.022>
- 73 Bushway, M.E., Gerber, S.A., Fenton, B.M., Miller, R.K., Lord, E.M. and Murphy, S.P. (2014) Morphological and phenotypic analyses of the human placenta using whole mount immunofluorescence. *Biol. Reprod.* **90**, 110, <https://doi.org/10.1095/biolreprod.113.115915>
- 74 Magee, L.A., Brown, M.A., Hall, D.R., Gupta, S., Hennessy, A., Karumanchi, S.A. et al. (2022) The 2021 International Society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens.* **27**, 148–169, <https://doi.org/10.1016/j.preghy.2021.09.008>
- 75 Gaccioli, F., Sovio, U., Gong, S., Cook, E., Charnock-Jones, D.S. and Smith, G.C.S. (2022) Increased placental sFLT1 (soluble fms-like tyrosine kinase receptor-1) drives the antiangiogenic profile of maternal serum preceding preeclampsia but not fetal growth restriction. *Hypertension* **80**, 325–334
- 76 Benton, S.J., McCowan, L.M., Heazell, A.E., Gynspan, D., Hutcheon, J.A., Senger, C. et al. (2016) Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. *Placenta* **42**, 1–8, <https://doi.org/10.1016/j.placenta.2016.03.010>
- 77 Spiel, M., Salahuddin, S., Pernicone, E., Zsengeller, Z., Wang, A., Modest, A.M. et al. (2017) Placental soluble fms-like tyrosine kinase expression in small for gestational age infants and risk for adverse outcomes. *Placenta* **52**, 10–16, <https://doi.org/10.1016/j.placenta.2017.02.011>
- 78 Kwiatkowski, S., Bednarek-Jedrzejek, M., Ksel, J., , Tousty, P., Kwiatkowska, E., Cymbaluk, A. et al. (2018) sFlt-1/PlGF and Doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below 10th percentile. *Pregnancy Hypertens.* **14**, 79–85, <https://doi.org/10.1016/j.preghy.2018.08.448>
- 79 Baekgaard Thorsen, L.H., Bjørkholm Andersen, L., Birukov, A., Lykkedegn, S., Dechend, R., Stener Jørgensen, J. et al. (2020) Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study. *J. Matern. Fetal Neonatal Med.* **33**, 1377–1384

- 80 Garcia-Manau, P., Mendoza, M., Bonacina, E., Garrido-Gimenez, C., Fernandez-Oliva, A., Zanini, J. et al. (2021) Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age. *Acta Obstet. Gynecol. Scand.* **100**, 119–128, <https://doi.org/10.1111/aogs.13978>
- 81 Kwiatkowski, S., Bednarek-Jedrzejek, M., Kwiatkowska, E., Cymbaluk-Ploska, A. and Torbe, A. (2021) Diagnosis of placental insufficiency independently of clinical presentations using sFit-1/PLGF ratio, including SGA patients. *Pregnancy Hypertens* **25**, 244–248, <https://doi.org/10.1016/j.pregphy.2021.07.245>
- 82 Andrikos, A., Andrikos, D., Schmidt, B., Birdir, C., Kimmig, R., Gellhaus, A. et al. (2022) Course of the sFit-1/PIGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery. *Arch. Gynecol. Obstet.* **305**, 597–605, <https://doi.org/10.1007/s00404-021-06186-5>
- 83 Mitlid-Mork, B., Bowe, S., Staff, A.C. and Sugulle, M. (2022) Alterations in maternal sFit-1 and PIGF: Time to labor onset in term-/late-term pregnancies with and without placental dysfunction. *Pregnancy Hypertens* **30**, 148–153, <https://doi.org/10.1016/j.pregphy.2022.10.004>
- 84 Quezada, M.S., Rodriguez-Calvo, J., Villalain, C., Gomez-Arriaga, P.I., Galindo, A. and Herraiz, I. (2020) sFit-1/PIGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow. *Ultrasound Obstet. Gynecol.* **56**, 549–556, <https://doi.org/10.1002/uog.21949>
- 85 Bonacina, E., Mendoza, M., Farras, A., Garcia-Manau, P., Serrano, B., Hurtado, I. et al. (2022) Angiogenic factors for planning fetal surveillance in fetal growth restriction and small-for-gestational-age fetuses: a prospective observational study. *BJOG* **129**, 1870–1877, <https://doi.org/10.1111/1471-0528.17151>
- 86 Gaccioli, F., Sovio, U., Cook, E., Hund, M., Charnock-Jones, D.S. and Smith, G.C.S. (2018) Screening for fetal growth restriction using ultrasound and the sFLT1/PIGF ratio in nulliparous women: a prospective cohort study. *Lancet Child Adolesc. Health* **2**, 569–581, [https://doi.org/10.1016/S2352-4642\(18\)30129-9](https://doi.org/10.1016/S2352-4642(18)30129-9)
- 87 Shinohara, S., Uchida, Y., Kasai, M. and Sunami, R. (2017) Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction. *Hypertens. Pregnancy* **36**, 269–275, <https://doi.org/10.1080/10641955.2017.1334800>
- 88 Bonacina, E., Armengol-Alsina, M., Hurtado, I., Garcia-Manau, P., Ferrer-Oliveras, R., Monreal, S. et al. (2022) sFit-1 to PIGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study. *J. Obstet. Gynaecol.* **42**, 2840–2845, <https://doi.org/10.1080/01443615.2022.2109956>
- 89 Lim, S., Li, W., Kemper, J., Nguyen, A., Mol, B.W. and Reddy, M. (2021) Biomarkers and the prediction of adverse outcomes in preeclampsia: a systematic review and meta-analysis. *Obstet. Gynecol.* **137**, 72–81, <https://doi.org/10.1097/AOG.0000000000004149>
- 90 Valino, N., Giunta, G., Gallo, D.M., Akolekar, R. and Nicolaides, K.H. (2016) Biophysical and biochemical markers at 35–37 weeks' gestation in the prediction of adverse perinatal outcome. *Ultrasound Obstet. Gynecol.* **47**, 203–209, <https://doi.org/10.1002/uog.15663>
- 91 Fadigas, C., Peeva, G., Mendez, O., Poon, L.C. and Nicolaides, K.H. (2015) Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35–37 weeks. *Ultrasound Obstet. Gynecol.* **46**, 191–197, <https://doi.org/10.1002/uog.14862>
- 92 Valino, N., Giunta, G., Gallo, D.M., Akolekar, R. and Nicolaides, K.H. (2016) Biophysical and biochemical markers at 30–34 weeks' gestation in the prediction of adverse perinatal outcome. *Ultrasound Obstet. Gynecol.* **47**, 194–202, <https://doi.org/10.1002/uog.14928>
- 93 Chen, W., Wei, Q., Liang, Q., Song, S. and Li, J. (2022) Diagnostic capacity of sFit-1/PIGF ratio in fetal growth restriction: a systematic review and meta-analysis. *Placenta* **127**, 37–42, <https://doi.org/10.1016/j.placenta.2022.07.020>
- 94 Birdir, C., Fryze, J., Frolich, S., Schmidt, M., Köninger, A., Kimmig, R. et al. (2017) Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFit-1 and PIGF at 11–13 weeks gestation on small for gestational age births. *J. Matern. Fetal Neonatal Med.* **30**, 629–634, <https://doi.org/10.1080/14767058.2016.1182483>
- 95 Triunfo, S., Crovetto, F., Rodriguez-Sureda, V., Scazzocchio, E., Crispi, F., Dominguez, C. et al. (2017) Changes in uterine artery Doppler velocimetry and circulating angiogenic factors in the first half of pregnancies delivering a small-for-gestational-age neonate. *Ultrasound Obstet. Gynecol.* **49**, 357–363, <https://doi.org/10.1002/uog.15978>
- 96 Crovetto, F., Triunfo, S., Crispi, F., Rodriguez-Sureda, V., Dominguez, C., Figueras, F. et al. (2017) Differential performance of first-trimester screening in predicting small-for-gestational-age neonate or fetal growth restriction. *Ultrasound Obstet. Gynecol.* **49**, 349–356, <https://doi.org/10.1002/uog.15919>
- 97 Birdir, C., Droste, L., Fox, L., Frank, M., Fryze, J., Enekwe, A. et al. (2018) Predictive value of sFit-1, PIGF, sFit-1/PIGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37weeks of pregnancy. *Pregnancy Hypertens* **12**, 124–128, <https://doi.org/10.1016/j.pregphy.2018.04.010>
- 98 Herraiz, I., Droge, L.A., Gomez-Montes, E., Henrich, W., Galindo, A. and Verlohren, S. (2014) Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. *Obstet. Gynecol.* **124**, 265–273, <https://doi.org/10.1097/AOG.0000000000000367>
- 99 Conde-Agudelo, A., Papageorgiou, A.T., Kennedy, S.H. and Villar, J. (2013) Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. *BJOG* **120**, 681–694, <https://doi.org/10.1111/1471-0528.12172>
- 100 Sherrell, H., Dunn, L., Clifton, V. and Kumar, S. (2018) Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **225**, 26–34, <https://doi.org/10.1016/j.ejogrb.2018.03.059>
- 101 Witwicki, J., Chaberek, K., Szymecka-Samaha, N., Krysiak, A., Pietruski, P. and Kosinska-Kaczynska, K. (2021) sFit-1/PIGF ratio in prediction of short-term neonatal outcome of small for gestational age neonates. *Children (Basel)* **8**, 718, <https://doi.org/10.3390/children8080718>
- 102 Shim, S.H., Jeon, H.J., Ryu, H.J., Kim, S.H., Min, S.G., Kang, M.K. et al. (2021) Prenatal serum sFit-1/PIGF ratio predicts the adverse neonatal outcomes among small-for-gestational-age fetuses in normotensive pregnant women: A prospective cohort study. *Medicine (Baltimore)*. **100**, e24681, <https://doi.org/10.1097/MD.00000000000024681>

- 103 Arenas, G.A., Docheva, N., Lopes Perdigao, J., Mueller, A., Dada, T. and Rana, S. (2022) Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. *Pregnancy Hypertens* **29**, 108–115, <https://doi.org/10.1016/j.preghy.2022.07.003>
- 104 Lafuente-Ganuza, P., Lequerica-Fernandez, P., Carretero, F., Escudero, A.I., Martinez-Morillo, E., Sabria, E. et al. (2020) A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PIGF ratio and NT-proBNP as biomarkers. *Clin. Chem. Lab. Med.* **58**, 399–407, <https://doi.org/10.1515/ccclm-2019-0939>
- 105 Sabria, E., Lequerica-Fernandez, P., Lafuente-Ganuza, P., Eguia-Ángeles, E., Escudero, A.I., Martínez-Morillo, E. et al. (2018) Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study. *Ultrasound Obstet. Gynecol.* **51**, 758–767, <https://doi.org/10.1002/uog.19040>
- 106 Martinez-Varea, A., Martinez-Saez, C., Domenech, J., Desco-Blay, J., Monfort-Pitarch, S., Hueso, M. et al. (2022) sFlt-1/PIGF ratio at 24 weeks gestation in twin pregnancies as a predictor of preeclampsia or fetal growth restriction. *Fetal Diagn. Ther.* **49**, 206–214, <https://doi.org/10.1159/000525169>
- 107 Boucoiran, I., Thissier-Levy, S., Wu, Y., Wei, S.Q., Luo, Z.C., Delvin, E. et al. (2013) Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. *Am. J. Perinatol.* **30**, 607–612
- 108 Levine, R.J., Lam, C., Qian, C., Yu, K.F., Maynard, S.E., Sachs, B.P. et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N. Engl. J. Med.* **355**, 992–1005, <https://doi.org/10.1056/NEJMoa055352>
- 109 Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y.M. et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat. Med.* **12**, 642–649, <https://doi.org/10.1038/nm1429>
- 110 Margioulas-Siarkou, G., Margioulas-Siarkou, C., Petousis, S., Margaritis, K., Vavoulidis, E., Gullo, G. et al. (2022) The role of endoglin and its soluble form in pathogenesis of preeclampsia. *Mol. Cell. Biochem.* **477**, 479–491, <https://doi.org/10.1007/s11010-021-04294-z>
- 111 Stepan, H., Kramer, T. and Faber, R. (2007) Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. *J. Clin. Endocrinol. Metab.* **92**, 2831–2834, <https://doi.org/10.1210/jc.2006-2774>
- 112 Iannaccone, A., Reisch, B., Mavarani, L., Darkwah Oppong, M., Kimmig, R., Mach, P. et al. (2022) Soluble endoglin versus sFlt-1/PIGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort. *Hypertens. Pregnancy* **41**, 159–172, <https://doi.org/10.1080/10641955.2022.2066119>
- 113 Erol Deniz, M., Deniz, A., Mendilcioglu, I., Sanhal, C.Y., Ozdem, S., Kucukcetin, I.O. et al. (2021) Serial measurement of soluble endoglin for risk assessment at the diagnosis of fetal growth restriction. *Int. J. Clin. Pract.* **75**, e14840, <https://doi.org/10.1111/ijcp.14840>
- 114 Rafi, I. and Chitty, L. (2009) Cell-free fetal DNA and non-invasive prenatal diagnosis. *Br. J. Gen. Pract.* **59**, e146–e148, <https://doi.org/10.3399/bjgp09X420572>
- 115 van der Schoot, C.E., Hahn, S. and Chitty, L.S. (2008) Non-invasive prenatal diagnosis and determination of fetal Rh status. *Semin. Fetal Neonatal Med.* **13**, 63–68, <https://doi.org/10.1016/j.siny.2007.12.012>
- 116 Norton, M.E., Jacobsson, B., Swamy, G.K., Laurent, L.C., Ranzini, A.C., Brar, H. et al. (2015) Cell-free DNA analysis for noninvasive examination of trisomy. *N. Engl. J. Med.* **372**, 1589–1597, <https://doi.org/10.1056/NEJMoa1407349>
- 117 Alberry, M.S., Maddocks, D.G., Hadi, M.A., Metawi, H., Hunt, L.P., Abdel-Fattah, S.A. et al. (2009) Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. *Am. J. Obstet. Gynecol.* **200**, 98e91–98e96, <https://doi.org/10.1016/j.ajog.2008.07.063>
- 118 Caramelli, E., Rizzo, N., Concu, M., Simonazzi, G., Carinci, P., Bondavalli, C. et al. (2003) Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction—a pilot study. *Prenat. Diagn.* **23**, 367–371, <https://doi.org/10.1002/pd.596>
- 119 Smid, M., Vassallo, A., Lagona, F., Valsecchi, L., Maniscalco, L., Danti, L. et al. (2001) Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. *Ann. N. Y. Acad. Sci.* **945**, 132–137, <https://doi.org/10.1111/j.1749-6632.2001.tb03873.x>
- 120 Rolnik, D.L., da Silva Costa, F., Lee, T.J., Schmid, M. and McLennan, A.C. (2018) Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. *Ultrasound Obstet. Gynecol.* **52**, 722–727, <https://doi.org/10.1002/uog.18993>
- 121 Morano, D., Rossi, S., Lapucci, C., Pittalis, M.C. and Farina, A. (2018) Cell-free DNA (cfDNA) fetal fraction in early- and late-onset fetal growth restriction. *Mol. Diagn. Ther.* **22**, 613–619, <https://doi.org/10.1007/s40291-018-0353-9>
- 122 Adiyaman, D., Konuralp Atakul, B., Kuyucu, M., Toklu, G., Golbasi, H., Koc, A. et al. (2020) Can fetal fractions in the cell-free DNA test predict the onset of fetal growth restriction? *J. Perinat. Med.* **48**, 395–401, <https://doi.org/10.1515/jpm-2020-0010>
- 123 Smid, M., Galbiati, S., Lojaco, A., Valsecchi, L., Platto, C., Cavoretto, P. et al. (2006) Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. *Prenat. Diagn.* **26**, 785–790, <https://doi.org/10.1002/pd.1504>
- 124 Poon, L.C., Musci, T., Song, K., Syngelaki, A. and Nicolaides, K.H. (2013) Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. *Fetal Diagn. Ther.* **33**, 215–223, <https://doi.org/10.1159/000346806>
- 125 Sekizawa, A., Jimbo, M., Saito, H., Iwasaki, M., Matsuoka, R., Okai, T. et al. (2003) Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. *Am. J. Obstet. Gynecol.* **188**, 480–484, <https://doi.org/10.1067/mob.2003.27>
- 126 Carbone, I.F., Conforti, A., Picarelli, S., Morano, D., Alviggi, C. and Farina, A. (2020) Circulating nucleic acids in maternal plasma and serum in pregnancy complications: are they really useful in clinical practice? A systematic review. *Mol. Diagn. Ther.* **24**, 409–431, <https://doi.org/10.1007/s40291-020-00468-5>
- 127 Sifakis, S., Koukou, Z. and Spandidos, D.A. (2015) Cell-free fetal DNA and pregnancy-related complications (review). *Mol. Med. Rep.* **11**, 2367–2372, <https://doi.org/10.3892/mmr.2014.3118>

- 128 Scheffer, P.G., Wirjosekarto, S.A.M., Becking, E.C., Weiss, M.M., Bax, C.J., Oepkes, D. et al. (2021) Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: a systematic review. *Prenat. Diagn.* **41**, 1287–1295, <https://doi.org/10.1002/pd.6028>
- 129 Lagos-Quintana, M., Rauhut, R., Lendeckel, W. and Tuschl, T. (2001) Identification of novel genes coding for small expressed RNAs. *Science* **294**, 853–858, <https://doi.org/10.1126/science.1064921>
- 130 Chim, S.S., Shing, T.K., Hung, E.C., Leung, T.Y., Lau, T.K., Chiu, R.W. et al. (2008) Detection and characterization of placental microRNAs in maternal plasma. *Clin. Chem.* **54**, 482–490, <https://doi.org/10.1373/clinchem.2007.097972>
- 131 Arroyo, J.D., Chevillet, J.R., Kroh, E.M., , Ruf, I.K., Pritchard, C.C., Gibson, D.F. et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 5003–5008, <https://doi.org/10.1073/pnas.1019055108>
- 132 Fu, G., Brkic, J., Hayder, H. and Peng, C. (2013) MicroRNAs in human placental development and pregnancy complications. *Int. J. Mol. Sci.* **14**, 5519–5544, <https://doi.org/10.3390/ijms14035519>
- 133 Luo, S.S., Ishibashi, O., Ishikawa, G., Ishikawa, T., Katayama, A., Mishima, T. et al. (2009) Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. *Biol. Reprod.* **81**, 717–729, <https://doi.org/10.1095/biolreprod.108.075481>
- 134 Hromadnikova, I., Kotlabova, K., Hympanova, L. and Krofta, L. (2015) Cardiovascular and cerebrovascular disease associated microRNAs are dysregulated in placental tissues affected with gestational hypertension, preeclampsia and intrauterine growth restriction. *PLoS ONE* **10**, e0138383, <https://doi.org/10.1371/journal.pone.0138383>
- 135 Hromadnikova, I., Kotlabova, K. and Krofta, L. (2022) First-trimester screening for fetal growth restriction and small-for-gestational-age pregnancies without preeclampsia using cardiovascular disease-associated microRNA biomarkers. *Biomedicine* **10**, 718, <https://doi.org/10.3390/biomedicine10030718>
- 136 Kim, S.H., MacIntyre, D.A., Binkhamis, R., Cook, J., Bennett, P.R. et al. (2020) Maternal plasma miRNAs as potential biomarkers for detecting risk of small-for-gestational-age births. *EBioMedicine* **62**, 103145, <https://doi.org/10.1016/j.ebiom.2020.103145>
- 137 Rodosthenous, R.S., Burris, H.H., Sanders, A.P., Just, A.C., Dereix, A.E., Svensson, K. et al. (2017) Second trimester extracellular microRNAs in maternal blood and fetal growth: an exploratory study. *Epigenetics* **12**, 804–810, <https://doi.org/10.1080/15592294.2017.1358345>
- 138 Tagliaferri, S., Cepparulo, P., Vinciguerra, A., Campanile, M., Esposito, G., Maruotti, G.M. et al. (2021) miR-16-5p, miR-103-3p, and miR-27b-3p as early peripheral biomarkers of fetal growth restriction. *Front. Pediatr.* **9**, 611112, <https://doi.org/10.3389/fped.2021.611112>
- 139 Tsai, P.Y., Li, S.H., Chen, W.N., Tsai, H.L. and Su, M.T. (2017) Differential miR-346 and miR-582-3p expression in association with selected maternal and fetal complications. *Int. J. Mol. Sci.* **18**, 1570, <https://doi.org/10.3390/ijms18071570>
- 140 Whitehead, C.L., Teh, W.T., Walker, S.P., Leung, C., Larmour, L. and Tong, S. (2013) Circulating microRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. *PLoS ONE* **8**, e78487, <https://doi.org/10.1371/journal.pone.0078487>
- 141 Anton, L., Olarerin-George, A.O., Schwartz, N., Srinivas, S., Basteck, J., Hogenesch, J.B. et al. (2013) miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. *Am. J. Pathol.* **183**, 1437–1445, <https://doi.org/10.1016/j.ajpath.2013.07.021>
- 142 Luo, R., Wang, Y., Xu, P., Cao, G., Zhao, Y., Shao, X. et al. (2016) Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I domain containing 7A. *Sci. Rep.* **6**, 19588, <https://doi.org/10.1038/srep19588>
- 143 Bian, X., Liu, J., Yang, Q., Liu, Y., Jia, W., Zhang, X. et al. (2021) MicroRNA-210 regulates placental adaptation to maternal hypoxic stress during pregnancy. *Biol. Reprod.* **104**, 418–429, <https://doi.org/10.1093/biolre/iaaa187>
- 144 Maccani, M.A., Padbury, J.F. and Marsit, C.J. (2011) miR-16 and miR-21 expression in the placenta is associated with fetal growth. *PLoS ONE* **6**, e21210, <https://doi.org/10.1371/journal.pone.0021210>
- 145 Higashijima, A., Miura, K., Mishima, H., Kinoshita, A., Jo, O., Abe, S. et al. (2013) Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy. *Prenat. Diagn.* **33**, 214–222, <https://doi.org/10.1002/pd.4045>
- 146 Hromadnikova, I., Kotlabova, K., Hympanova, L. and Krofta, L. (2016) Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood. *Thromb. Res.* **137**, 126–140, <https://doi.org/10.1016/j.thromres.2015.11.032>
- 147 Parry, S., Carper, B.A., Grobman, W.A., , Wapner, R.J., Chung, J.H., Haas, D.M. et al. (2022) Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. *Am. J. Obstet. Gynecol.* **227**, 497e491e413–497e497e413, <https://doi.org/10.1016/j.ajog.2022.03.064>
- 148 Stepan, H., Galindo, A., Hund, M., Schlembach, D., Sillman, J., Surbek, D. et al. (2022) Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. *Ultrasound Obstet. Gynecol.* **61**, 168–180
- 149 Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A.C., Sennström, M. et al. (2016) Predictive Value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. *N. Engl. J. Med.* **374**, 13–22, <https://doi.org/10.1056/NEJMoa1414838>
- 150 Yu, N., Cui, H., Chen, X. and Chang, Y. (2017) First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction. *Taiwan J. Obstet. Gynecol.* **56**, 358–361, <https://doi.org/10.1016/j.tjog.2017.01.009>
- 151 Fruscalzo, A., Frommer, J., Londero, A.P., Henze, A., Schweigert, F.J., Nofer, J.R. et al. (2017) First trimester TTR-RBP4-ROH complex and angiogenic factors in the prediction of small for gestational age infant's outcome. *Arch. Gynecol. Obstet.* **295**, 1157–1165, <https://doi.org/10.1007/s00404-017-4338-4>
- 152 Hendrix, M.L.E., Bons, J.A.P., Snellings, R.R.G., Bekers, O., van Kuijk, S.M.J., Spaanderman, M.E.A. et al. (2019) Can fetal growth velocity and first trimester maternal biomarkers improve the prediction of small-for-gestational age and adverse neonatal outcome? *Fetal Diagn. Ther.* **46**, 274–284, <https://doi.org/10.1159/000499580>
- 153 Furuta, I., Umazume, T., Kojima, T., Chiba, K., Nakagawa, K., Hosokawa, A. et al. (2017) Serum placental growth factor and soluble fms-like tyrosine kinase 1 at mid-gestation in healthy women: association with small-for-gestational-age neonates. *J. Obstet. Gynaecol. Res.* **43**, 1152–1158, <https://doi.org/10.1111/jog.13340>

- 154 Ciobanou, A., Jabak, S., De Castro, H., Frei, L., Akolekar, R. and Nicolaides, K.H. (2019) Biomarkers of impaired placentation at 35–37 weeks' gestation in the prediction of adverse perinatal outcome. *Ultrasound Obstet. Gynecol.* **54**, 79–86, <https://doi.org/10.1002/uog.20346>
- 155 Shibata, E., Rajakumar, A., Powers, R.W., Larkin, R.W., Gilmour, C., Bodnar, L.M. et al. (2005) Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. *J. Clin. Endocrinol. Metab.* **90**, 4895–4903, <https://doi.org/10.1210/jc.2004-1955>
- 156 Wallner, W., Sengenberger, R., Strick, R., Strissel, P.L., Meurer, B., Beckmann, M.W. et al. (2007) Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. *Clin. Sci. (Lond.)* **112**, 51–57, <https://doi.org/10.1042/CS20060161>
- 157 MacDonald, T.M., Tran, C., Kaitu'u-Lino, T.J., Brennecke, S.P., Hiscock, R.J., Hui, L. et al. (2018) Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. *BMC Pregnancy Childbirth* **18**, 354, <https://doi.org/10.1186/s12884-018-1992-x>
- 158 Darling, A.M., McDonald, C.R., Conroy, A.L., Hayford, K.T., Liles, W.C., Wang, M. et al. (2014) Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania. *Am. J. Obstet. Gynecol.* **211**, 509e501–509e508, <https://doi.org/10.1016/j.ajog.2014.05.032>
- 159 Triunfo, S., Parra-Saavedra, M., Rodriguez-Sureda, V., Crovetto, F., Dominguez, C., Gratacós, E. et al. (2016) Angiogenic factors and doppler evaluation in normally growing fetuses at routine third-trimester scan: prediction of subsequent low birth weight. *Fetal Diagn. Ther.* **40**, 13–20, <https://doi.org/10.1159/000440650>
- 160 Thadhani, R., Mutter, W.P., Wolf, M., Levine, R.J., Taylor, R.N., Sukhatme, V.P. et al. (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. *J. Clin. Endocrinol. Metab.* **89**, 770–775, <https://doi.org/10.1210/jc.2003-031244>
- 161 Rizos, D., Eleftheriades, M., Karampas, G., Rizou, M., Haliassos, A., Hassiakos, D. et al. (2013) Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **171**, 225–230, <https://doi.org/10.1016/j.ejogrb.2013.08.040>
- 162 Borrás, D., Perales-Puchalt, A., Ruiz Sacedon, N. and Perales, A. (2014) Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction. *J. Obstet. Gynaecol.* **34**, 218–220, <https://doi.org/10.3109/01443615.2013.834304>
- 163 Savvidou, M.D., Yu, C.K., Harland, L.C., Hingorani, A.D. and Nicolaides, K.H. (2006) Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. *Am. J. Obstet. Gynecol.* **195**, 1668–1673, <https://doi.org/10.1016/j.ajog.2006.03.065>
- 164 Chaiworapongsa, T., Espinoza, J., Gotsch, F., Kim, Y.M., Kim, G.J., Goncalves, L.F. et al. (2008) The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. *J. Matern. Fetal Neonatal Med.* **21**, 25–40, <https://doi.org/10.1080/14767050701832833>
- 165 Boutsikou, T., Malamitsi-Puchner, A., Economou, E., Boutsikou, M., Puchner, K.P. and Hassiakos, D. (2006) Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. *Early Hum. Dev.* **82**, 235–239, <https://doi.org/10.1016/j.earlhumdev.2005.09.010>
- 166 Asvold, B.O., Vatten, L.J., Romundstad, P.R., Jenum, P.A., Karumanchi, S.A. and Eskild, A. (2011) Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. *Am. J. Epidemiol.* **173**, 630–639, <https://doi.org/10.1093/aje/kwq373>
- 167 Wathen, K.A., Tuutti, E., Stenman, U.H., Alfthan, H., Halmesmaki, E., Finne, P. et al. (2006) Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. *J. Clin. Endocrinol. Metab.* **91**, 180–184, <https://doi.org/10.1210/jc.2005-1076>
- 168 Nanjo, S., Minami, S., Mizoguchi, M., Yamamoto, M., Yahata, T., Toujima, S. et al. (2017) Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction. *J. Obstet. Gynaecol. Res.* **43**, 1805–1814, <https://doi.org/10.1111/jog.13452>
- 169 Kochhar, P., Vukku, M., Rajashekhar, R. and Mukhopadhyay, A. (2022) microRNA signatures associated with fetal growth restriction: a systematic review. *Eur. J. Clin. Nutr.* **76**, 1088–1102, <https://doi.org/10.1038/s41430-021-01041-x>
- 170 Ashraf, U.M., Hall, D.L., Rawls, A.Z. and Alexander, B.T. (2021) Epigenetic processes during preeclampsia and effects on fetal development and chronic health. *Clin. Sci. (Lond.)* **135**, 2307–2327, <https://doi.org/10.1042/CS20190070>
- 171 Hornakova, A., Kolkova, Z., Holubekova, V., Loderer, L., Lasabova, Z., Biringer, K. et al. (2020) Diagnostic potential of microRNAs as biomarkers in the detection of preeclampsia. *Genet Test Mol. Biomarkers* **24**, 321–327, <https://doi.org/10.1089/gtmb.2019.0264>
- 172 Sheikh, A.M., Small, H.Y., Currie, G. and Delles, C. (2016) Systematic review of micro-RNA expression in pre-eclampsia identifies a number of common pathways associated with the disease. *PLoS ONE* **11**, e0160808, <https://doi.org/10.1371/journal.pone.0160808>